CD33 positive

In addition, elevated CD163 and CD133 levels were positively correlated with poorer prognosis in patients with CRC. In conclusion, it was suggested that different TAM phenotypes in combination with CSC-related biomarkers serve as potential biomarkers for CRC onset and progression.

The patient achieved sustained remission following risk-adapted AML chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT). This case underscores three critical points in pediatric AML: (1) the essential role of integrated molecular profiling in resolving morphologic ambiguities to prevent misclassification; (2) the complex prognostic impact of FLT3-ITD/NPM1 co-mutations in childhood AML; and (3) the potential therapeutic efficacy of allo-HSCT for rare fusion-driven subtypes.

Our findings indicate that CBR1 expression is elevated in NSCLC tissues and cell lines, and further increases in the presence of cisplatin (CDDP)...In A549 xenografts, combined PP-Me and CDDP therapy significantly inhibited tumor growth compared to either treatment alone. In conclusion, CBR1 inhibition enhances CDDP chemosensitivity by suppressing stemness and quiescence in NSCLC.

P2, N=19, Active, not recruiting, Centre Antoine Lacassagne | Recruiting --> Active, not recruiting | N=50 --> 19 | Trial completion date: Mar 2027 --> Jul 2028 | Trial primary completion date: Mar 2027 --> Jul 2028

P=N/A, N=165, Recruiting, Pfizer | Trial completion date: Nov 2027 --> Apr 2027 | Trial primary completion date: Nov 2027 --> Apr 2027

AML1-ETO fusion gene positive acute myeloid leukemia with basophilic granulocytosis is a rare type of leukemia, and its pathogenesis, diagnosis, treatment, and prognosis are unique. In-depth study of such cases, combined with the review of relevant literature, is helpful to further reveal the pathogenesis of leukemia, provide more evidence for clinical diagnosis and treatment, so as to improve the level of diagnosis and treatment and improve the prognosis of patients.

P2, N=50, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Nov 2025 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2027

P1, N=21, Completed, Uma Borate | Active, not recruiting --> Completed

To date, only antibody-drug conjugates have reached regulatory approval, with gemtuzumab ozogamicin approved in combination with intensive induction and consolidation therapy for newly diagnosed CD33-positive AML...This review will introduce the current immunotherapy platforms under investigation in AML, starting with antibody-based approaches, followed by T-cell redirecting therapies, and culminating in an overview of immune resistance, the bone marrow microenvironment, and strategies toward personalized combinatorial immunotherapy. By synthesizing recent clinical data and mechanistic insights, including those from early CAR and T-cell engager trials, we aim to provide a translational framework for how immunotherapy might still reshape AML care-through integration of immune contexture of the bone marrow environment aiming for rational combinatorial approaches.

P1, N=20, Recruiting, First Affiliated Hospital of Zhejiang University

P2, N=50, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

Between March 2020 and February 2023, 34 consecutive fit CD33+ AML patients, median age 54.5 years (range, 25-75) were treated. This study confirms the efficacy and toxicity data reported in clinical trials, highlighting the feasibility of GO based chemotherapy also in patients older than 60 years and as a bridge to allo-HSCT.